Our interview with Geert Kersten is out now. We talked about the current market for cancer treatment globally, why his company is targeting head and neck cancer, and the potential for a successful cancer drug. View our exclusive preview clip below.
Geert Kersten has served in his current leadership role as Director and Chief Executive Officer at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI from the early days of its inception since 1987. He has been involved in the pioneering field of cancer immunotherapy for almost two decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry.
Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how the company’s Multikine product will change the way cancer is treated. Prior to CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from Millfield School in England, and completed his studies in the US. Mr. Kersten completed his Undergraduate Degree in Accounting, received an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. Mr. Kersten is also the inventor of a patent on the potential use of Multikine in managing cholesterol. You can find out more at: https://cel-sci.com/
Cel-Sci Corp gives us an overview for the possible potential for a successful cancer treatment company - View here.
Follow us on Twitter and Facebook for all the latest updates.
Palisade Radio / Twitter / Facebook
View disclaimer here.
